A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the
drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage
of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to
cause DNA damage of skin cells, as well as the extent of skin repair before and after
treatment.